Toyama Chemical Files New Drug Application for New-type Quinolone Antibiotic.Tokyo, Japan, June 5, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Toyama Chemical has filed a new drug application for T-3811, its proprietary antibiotic agent, with the Ministry of Health, Labor and Welfare. A new-type quinolone antibiotic, T-3811 has a wide antibacterial spectrum and beneficial effects on PRSPuiPenicillin-resistant Streptococcus streptococcus (strĕp'təkŏk`əs), any of a group of gram-positive bacteria, genus Streptococcus, some of which cause disease. pneumoniaeujand MRSA MRSA Methicillin-resistant Staphylococcus aureus. See MARSA. (Methicillin-resistant Staphylococcus aureus methicillin-resistant Staphylococcus aureus Methicillin-aminoglycoside resistant Staphylococcus aureus, MRSA An organism with multiple antibiotic resistances–eg, aminoglycosides, chloramphenicol, clindamycin, erythromycin, rifampin, tetracycline, ). Upon receiving approval, Toyama Chemical will collaborate with Taisho Pharmaceutical, Taisho Toyama Chemical and Astellas Pharma to promote the agent. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion